ArticleAnalytical and bioanalytical chemistry2026
Resolving charge and glycosylation variants of cetuximab combining offline ion-exchange and hydrophilic interaction chromatography-HRMS.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biopharmaceuticals, such as monoclonal antibodies (mAb), are complex molecules that require thorough analysis due to post-translational modifications, including charge variants and glycoform patterns. When analyzing intact mAbs, single liquid chromatography (LC) mass spectrometry (MS) methods often lack the resolution to distinguish this heterogeneity because they offer limited separation in both chromatographic and mass dimensions. Consequently, these methods struggle to detect low-abundance species, highlighting the importance of 2DLC-MS workflows. Here, we demonstrate the potential of the offline ion exchange chromatography (IEC)-hydrophilic interaction chromatography (HILIC)-MS method to effectively separate charge and glycoform variants of complex mAbs. Cetuximab served as the model antibody due to its multiple charge variants (arising from sialylation and C-terminal lysine clipping) and four glycosylation sites (in both Fab and Fc regions). Charge variants were first separated using non-volatile IEC and collected as individual fractions. These fractions were then analyzed using a low-flow HILIC-MS setup to increase sensitivity for low-abundance species. A RPLC trap column was used to desalt and reduce the volume transferred to the HILIC separation. The IEC-HILIC results showed that both Fc- and Fab-associated glycoforms of cetuximab were resolved to a level not achievable with HILIC-MS alone, allowing deeper insights into charge heterogeneity and glycosylation. In addition to resolving combined Fab/Fc glycoforms, the method also distinguished Fc-only glycoforms from the main isoform. This orthogonal IEC-HILIC method provides additional insights into charge and glycosylation heterogeneity, enabling a more comprehensive analysis of cetuximab. It provides an effective approach for detailed characterization of charge variations and glycoform diversity in next-generation protein therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.